LIVE FEED — OCT 29, 2026

Tempus AI’s $1.5 Billion Personalis Deal Tests Investor Patience on Genomics Bet

Tempus AI is pushing ahead with a roughly $1.5 billion all-stock acquisition of genomic testing company Personalis, a bet on expanding its precision oncology platform that sent both companies' shares…

Tempus AI's $1.5 Billion Personalis Deal Tests Investor Patience on Genomics Bet